EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link: https://ebookbell.com/faq

We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.

For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Anticoagulants Antiplatelets And Thrombolytics Methods In Molecular Medicine 1st Edition Shaker A Mousa

Name: Anticoagulants Antiplatelets And Thrombolytics Methods In Molecular Medicine 1st Edition Shaker A Mousa
SKU: BELL-2022290
Price: 31.00 USD
Availability: InStock
Rating: 4.4 (52 reviews)

SKU: BELL-2022290

$ 31.00 ~~$ 45.00~~ (-31%)

4.4

52 reviews

Anticoagulants Antiplatelets And Thrombolytics Methods In Molecular Medicine 1st Edition Shaker A Mousa instant download after payment.

Publisher: Humana Press

File Extension: PDF

File size: 1.69 MB

Pages: 320

Author: Shaker A. Mousa

ISBN: 9781588290830, 9781592596584, 1588290832, 1592596584

Language: English

Year: 2003

Edition: 1

Product desciption

Anticoagulants Antiplatelets And Thrombolytics Methods In Molecular Medicine 1st Edition Shaker A Mousa by Shaker A. Mousa 9781588290830, 9781592596584, 1588290832, 1592596584 instant download after payment.

1This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as the hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue factor targeting, platelet receptor targeting, and antithrombin III modulation.